on INTEGRAGEN (EPA:ALINT)
IntegraGen: two takeover bids filed in receivership
On September 11, 2026, IntegraGen, a genomics specialist, announced it had received two takeover bids as part of its insolvency proceedings initiated on June 15, 2026. The proposals came from Health In Code and ABL Diagnostics. They concern the acquisition of operations and assets through a sale plan. Details remain confidential for the time being.
The offers, financed with equity, require additional information, particularly regarding contracts and financial commitments. Conditions precedent, such as internal audits and approvals, still need to be met. None of the offers include a share buyback program, leaving shareholders exposed to potential losses.
The Commercial Court of Évry will rule on these offers at the hearing on October 5, 2026. IntegraGen's business continuity is assured, without interruption for its clients. The company remains committed to its ongoing projects.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTEGRAGEN news